IMPACT OF NON-PERSISTENCE TO SUBCUTANEOUS TNF-ALPHA INHIBITORS ON MEDICAL RESOURCE UTILIZATION AND COSTS

被引：0
|
作者：
Belhassen, M. [1 ]
Tubach, F. [2 ,3 ,4 ]
Hudry, C. [5 ]
Woronoff, M-C. [6 ]
Levy-Bachelot, L. [7 ]
Lamezec, L. [7 ]
Van Ganse, E. [1 ]
Fautrel, B. [8 ,9 ]
机构：
[1] Univ Claude Bernard Lyon 1, PELyon, Pharmacoepidemiol Lyon, Hesper 7425,Hlth Serv & Performance Res, Lyon, France
[2] Hop La Pitie Salpetriere, AP HP, Sante Publ & Informat Med, Ctr Pharmacoepidemiol Cephepl,Dept Biostat, Paris, France
[3] INSERM, UMR ECEVE 1123, Paris, France
[4] Univ Pierre & Marie Curie Paris 6, Sorbonne Univ, Paris, France
[5] Hop Cochin, AP HP, Paris, France
[6] Univ Franche Comte, Comue Ubfc, CHU Besancon, UMR INSERM 1098, Besancon, France
[7] Merck Sharp & Dohme Ltd, Paris, France
[8] UPMC Univ Paris 06, Sorbonne Univ, Paris, France
[9] Pitie Salpetriere Univ Hosp, AP HP, Dept Rheumatol, Paris, France
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2017年 / 76卷
关键词：
D O I：
10.1136/annrheumdis-2017-eular.2129
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0605
引用
收藏
页码：434 / 435
页数：2
相关论文
共 50 条
  • [1] Impact of Non-Persistence to Subcutaneous TNF-α Inhibitors on Medical Resource Utilization and Costs
    Belhassen, Manon
    Tubach, Florence
    Hudry, Christophe
    Woronoff, Marie-Christine
    Levy-Bachelot, Laurie
    Lamezec, Liliane
    Van Ganse, Eric
    Fautrel, Bruno
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 138 - 139
  • [2] Impact of Non-Persistence on Healthcare Resource Utilization and Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Study
    Carballo, Nuria
    Garcia-Alzorriz, Enric
    Ferrandez, Olivia
    Navarrete-Rouco, Maria Eugenia
    Duran-Jorda, Xavier
    Perez-Garcia, Carolina
    Monfort, Jordi
    Cots, Francesc
    Grau, Santiago
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [3] Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence
    Johan Dalén
    Axel Svedbom
    Christopher M. Black
    Ramon Lyu
    Qian Ding
    Shiva Sajjan
    Vasilisa Sazonov
    Sumesh Kachroo
    Rheumatology International, 2016, 36 : 987 - 995
  • [4] Impact of Non-Persistence on Healthcare Resource Utilization Costs in Patients With Immune-Mediated Rheumatic Diseases Initiating Subcutaneous TNF-Alpha Inhibitors: A Before-and-After Study (vol 12, 752879, 2021)
    Carballo, Nuria
    Garcia-Alzorriz, Enric
    Ferrandez, Olivia
    Navarrete-Rouco, Maria Eugenia
    Duran-Jorda, Xavier
    Perez-Garcia, Carolina
    Monfort, Jordi
    Cots, Francesc
    Grau, Santiago
    FRONTIERS IN PHARMACOLOGY, 2022, 13
  • [5] Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence
    Dalen, Johan
    Svedbom, Axel
    Black, Christopher M.
    Lyu, Ramon
    Ding, Qian
    Sajjan, Shiva
    Sazonov, Vasilisa
    Kachroo, Sumesh
    RHEUMATOLOGY INTERNATIONAL, 2016, 36 (07) : 987 - 995
  • [6] Treatment Persistence with Subcutaneous TNF-Alpha Inhibitors in France
    Belhassen, Manon
    Hudry, Christophe
    Woronoff, Marie-Christine
    Lamezec, Liliane
    Gouyette, Najat
    Ginoux, Marine
    Van Ganse, Eric
    Tubach, Florence
    Fautrel, Bruno
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [7] THE IMPACT OF NON-PERSISTENCE ON RESOURCE UTILIZATION COSTS IN IMMUNE-MEDIATED RHEUMATIC DISEASES
    Carballo, N.
    Garcia-Alzorriz Morral, E.
    Ferrandez-Quirante, O.
    Perez-Garcia, C.
    Navarrete-Rouco, M. E.
    Duran, X.
    Monfort, J.
    Cots, F.
    Grau, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 991 - 992
  • [8] THE IMPACT OF NON-PERSISTENCE ON THE DIRECT AND INDIRECT COSTS IN PATIENTS TREATED WITH SUBCUTANEOUS TUMOUR NECROSIS FACTOR-ALPHA INHIBITORS IN GERMANY
    Ziegelbauer, K.
    Huebinger, M.
    Dombrowski, S.
    Kostev, K.
    Friedrichs, M.
    Friedel, H.
    Kachroo, S.
    ANNALS OF THE RHEUMATIC DISEASES, 2018, 77 : 1834 - 1834
  • [9] The impact of non-persistence on the direct and indirect costs in patients treated with subcutaneous tumour necrosis factor-alpha inhibitors in Germany
    Ziegelbauer, Kathrin
    Kostev, Karel
    Huebinger, Maximilian
    Dombrowski, Silvia
    Friedrichs, Michael
    Friedel, Heiko
    Kachroo, Sumesh
    RHEUMATOLOGY, 2018, 57 (07) : 1276 - 1281
  • [10] The value of persistence in treatment with subcutaneous TNF-alpha inhibitors for ankylosing spondylitis
    Svedbom, Axel
    Dalen, Johan
    Ivergard, Moa
    Borse, Rebekah H.
    Black, Christopher M.
    Luttropp, Karin
    Kachroo, Sumesh
    EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2020, 21 (01): : 45 - 54
12345